-
ICOS/CD278 (RM417)
ICOS/CD278 (RM417)
- 中文名称：
- ICOS/CD278 (RM417)
- 英文名称：
- ICOS/CD278 (RM417)
- 品牌：
- AAA Biotech
- 品牌介绍：
- AAA Biotech专注于为全球生命科学研究提供高品质的蛋白质研究工具，核心产品包括经严格验证的抗体、重组蛋白及ELISA试剂盒。
- 货号：
- AAA59375
- 规格：
- 5 Slides|3 mL (RTU)|0.1 mL (Concentrate)|7 mL (RTU)|0.5 mL (Concentrate)
- 保存建议：
- Store at 2-8 degree C (Control Slides: Store at 20-25 degree C)
- 货期：
- 6-8周
- 来源宿主：
- Rabbit
- 反应种属：
- Human
- 免责声明：
- *本产品仅供科研实验使用，不得用于临床诊断。*
- 其他：
克隆性:Monoclonal
同型:IgG
克隆号:[RM417]
特异性:N/A
纯度:N/A
形式：Paraffin, Frozen
ICOS is a rabbit monoclonal antibody derived from cell culture supernatant that is concentrated, dialyzed, filter sterilized and diluted in buffer pH7.5, containing BSA and sodium azide as a preservative.
浓度：N/A
- 说明书：
CD278 is also known as inducible T-cell costimulatory molecule (ICOS). CD278 is homologous to the CD28/CTLA-4 proteins and is expressed on activated T cells and unstimulated thymocytes. CD278 plays a major role in regulation of cell-cell signaling, adaptive immune response, and cell proliferation. Interaction of CD278 and its ligand ICOS-L results in increased production of interleukins, which promote differentiation of Tfh and Tregs and development of Th1, Th2, and Th17 cells.
CD278/ICOS-L interaction has been shown to promote either antitumor T cell response or pro-tumor responses when triggered in Tregs (such as in Multiple Myeloma, Acute Myeloid Leukemia, and some invasive Breast Carcinomas). Therefore, both agonistic and antagonistic monoclonal antibodies targeting this pathway can be potential cancer immunotherapy.
ICOS antibody is primarily expressed on activated CD4+ and CD8+ T cells where it regulates immune responses and plays a role in the regulation of T Follicular helper cells. ICOS antibody is a sensitive marker for identifying T cell Lymphomas of Follicular Helper T cell origin, especially certain patterns of Angioimmunoblastic T-cell lymphoma (AITL) and Peripheral T-cell lymphomas with T-follicular Helper Phenotype (PTCL-TFH). This is becoming increasingly important given WHO 2016 test guidelines. Immunohistochemical analysis revealed that ICOS is widely expressed by malignant cells in skin biopsy specimens from patients with Mycosis Fungoides and Sézary syndrome (SS), as well as involved in node biopsy specimens from patients with SS.
